ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.465,69
-0,03%
S&P 500
5.180,74
1,03%
US Dollar vs BRL
5,0764
0,00%
Bitcoin
63.372,67
0,33%
Brent Oil
83,345
-0,16%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Biolase Inc (BIOL)

  7. Biolase Inc (BIOL) Notícias

BIOL

Biolase (BIOL)

Biolase Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BIOL
DataHoraFonteTítuloCódigoCompanhia
06/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIOLBiolase Inc
08/03/202408:31Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BIOLBiolase Inc
23/02/202418:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BIOLBiolase Inc
14/02/202415:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIOLBiolase Inc
14/02/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BIOLBiolase Inc
09/02/202410:44Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:BIOLBiolase Inc
29/01/202408:30PR Newswire (US)BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024NASDAQ:BIOLBiolase Inc
24/01/202419:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BIOLBiolase Inc
19/01/202408:09Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:BIOLBiolase Inc
08/01/202418:05PR Newswire (US)BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023NASDAQ:BIOLBiolase Inc
03/01/202418:05PR Newswire (US)BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARDNASDAQ:BIOLBiolase Inc
20/12/202316:13Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:BIOLBiolase Inc
14/12/202318:05PR Newswire (US)BIOLASE RECEIVES TOP WORKPLACES 2023 AWARDNASDAQ:BIOLBiolase Inc
12/12/202318:05PR Newswire (US)BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser TrialNASDAQ:BIOLBiolase Inc
08/12/202311:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BIOLBiolase Inc
06/12/202315:46PR Newswire (US)BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:BIOLBiolase Inc
09/11/202318:52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIOLBiolase Inc
09/11/202318:05PR Newswire (US)BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIESNASDAQ:BIOLBiolase Inc
08/11/202308:30PR Newswire (US)Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio ProtocolNASDAQ:BIOLBiolase Inc
07/11/202318:05PR Newswire (US)BIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9, 2023NASDAQ:BIOLBiolase Inc
18/10/202309:00PR Newswire (US)SWK Holdings Highlights Recent Achievements and Provides Portfolio UpdateNASDAQ:BIOLBiolase Inc
18/09/202317:30PR Newswire (US)BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and WarrantsNASDAQ:BIOLBiolase Inc
15/09/202318:27Edgar (US Regulatory)Form 424B1 - Prospectus [Rule 424(b)(1)]NASDAQ:BIOLBiolase Inc
14/09/202310:08Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:BIOLBiolase Inc
14/09/202300:16PR Newswire (US)BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and WarrantsNASDAQ:BIOLBiolase Inc
13/09/202322:25Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:BIOLBiolase Inc
10/08/202317:05PR Newswire (US)BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEARNASDAQ:BIOLBiolase Inc
02/08/202317:05PR Newswire (US)BIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023NASDAQ:BIOLBiolase Inc
26/07/202317:30PR Newswire (US)BIOLASE ANNOUNCES 1-FOR-100 REVERSE STOCK SPLITNASDAQ:BIOLBiolase Inc
17/07/202307:30PR Newswire (US)BIOLASE EPIC HYGIENE DENTAL LASER RECEIVES PRESTIGIOUS CELLERANT BEST OF CLASS HYGIENE AWARDNASDAQ:BIOLBiolase Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BIOL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HOOT4
HOTEIS OTHON PN
BOV
MNPR3
MINUPAR ON
BOV
PRIO3
PETRORIO ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
ENAT3
ENAUTA ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados